IOL Chemicals Share Price Surges By 3%; Receives EDQM Certificate Of Suitability For Clopidogrel Besilate API

IOL Chemicals and Pharmaceuticals Limited has received a Certificate of Suitability for its active pharmaceutical ingredient Clopidogrel Besilate. The certification was granted by the European Directorate for the Quality of Medicines & Health Care on February 23, 2026. 

Expanded Certification Portfolio 

With this approval, the company strengthens its regulatory portfolio for Clopidogrel-based APIs. It already holds a valid CEP for Clopidogrel Bisulphate, and the addition of Clopidogrel Besilate further broadens its product positioning in global markets. 

Clopidogrel is an antiplatelet medication widely used in the treatment and prevention of cardiovascular diseases, making it a critical therapy segment within the pharmaceutical industry. 

Strategic Implication 

The newly granted certificate enhances the company’s ability to supply high-quality cardiovascular APIs across regulated markets. It also reinforces IOL Chemicals’ presence in the global generics value chain through expanded product credentials. 

Read More: Himadri Speciality Chemical Share Price in Focus; Commences 70,000 MTPA Carbon Black Capacity at Mahistikry! 

IOL Chemicals and Pharmaceuticals Share Price Performance  

As of 25 February 2026, at 9:20 AM, IOL Chemicals and Pharmaceuticals Limited share price is trading at ₹74.20 per share, reflecting a  gain of 3.40% from the previous closing price. Over the past month, the stock has gained by 6.46%. 

Conclusion 

With the CEP for Clopidogrel Besilate now in place alongside its existing certification for Clopidogrel Bisulphate, IOL Chemicals strengthens its cardiovascular API portfolio and advances its global market footprint. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.